FDA greenlights Isembyld, the first therapy to combat SMA muscle loss
The FDA has approved Isembyld, the inaugural drug designed to address muscle wasting in spinal muscular atrophy, for patients aged two and older receiving SMN2-targeted treatments.
The Food and Drug Administration has granted approval to Isembyld, the first drug specifically targeting muscle degeneration in spinal muscular atrophy (SMA). Scholar Rock, the developer, says the therapy is intended for children two years of age and older as well as adults who are already receiving treatments that act on the SMN2 gene. A pivotal late-stage trial demonstrated that patients combining Isembyld with an SMN2-targeted medication improved their motor abilities over a twelve-month period, whereas the placebo group experienced a decline, a difference that reached statistical significance.
David Hallal, chief executive of Scholar Rock, described the approval as a defining moment after years of unsuccessful attempts to harness myostatin inhibition. The new option offers hope for greater independence in movement for those living with the rare neurological disorder.
Why it matters
It provides the first approved option to preserve muscle function in SMA, potentially improving mobility for patients.
In this story
